Core Insights - LENSAR, Inc. reported a total revenue of $14.3 million for Q3 2025, marking a 6% increase from $13.5 million in Q3 2024, primarily driven by an 11% increase in worldwide procedure volume [3][4] - The installed base of ALLY Robotic Cataract Laser Systems grew by 77% year-over-year, with 185 systems installed as of September 30, 2025 [3][4] - The company is in the process of being acquired by Alcon, with expectations for the transaction to close in Q1 2026 [2][3] Financial Performance - Total revenue for Q3 2025 was $14.3 million, up from $13.5 million in Q3 2024, driven by increased procedure volume [3][4] - Recurring revenue accounted for 75% of total revenue in Q3 2025, compared to 73% in Q3 2024 [4] - The net loss for Q3 2025 was $3.7 million, or ($0.31) per share, compared to a net loss of $1.5 million, or ($0.13) per share, in Q3 2024 [6][18] Operational Highlights - The company placed 18 ALLY Systems in Q3 2025, contributing to a total installed base of approximately 425 laser systems, a 20% increase from the previous year [3][4] - Selling, general, and administrative expenses rose to $12.0 million in Q3 2025, up from $6.1 million in Q3 2024, largely due to acquisition-related costs [5][18] - Research and development expenses increased by 14% to $1.4 million in Q3 2025 compared to $1.2 million in Q3 2024 [5][18] Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and investments totaling $16.9 million, down from $22.5 million at the end of 2024 [8][20] - The cash balance decreased by approximately $3.4 million during Q3 2025 [8]

Core Insights - LENSAR, Inc. reported strong operational performance in Q2 2025, with 18 ALLY Robotic Cataract Laser Systems installed and an additional 18 in backlog, reflecting a 107% growth in the installed base compared to Q2 2024 [1][2] - The company experienced a 23% increase in worldwide procedure volumes compared to the same quarter in the previous year [1][2] - The proposed merger with Alcon has received overwhelming support from shareholders, with over 99% of votes cast in favor, and is expected to close by the end of 2025 [2] Financial Performance - Total revenue for Q2 2025 was $13.9 million, a 10% increase from $12.6 million in Q2 2024, primarily driven by increased procedure volume [3][4] - Recurring revenue accounted for 82% of total revenue in Q2 2025, up from 79% in Q2 2024, with procedure revenue increasing to $8.3 million from $6.9 million year-over-year [4][5] - The net loss for Q2 2025 was $1.8 million, or ($0.15) per share, significantly reduced from a net loss of $9.0 million, or ($0.79) per share, in Q2 2024 [7][20] Operational Highlights - The installed base of ALLY Systems reached approximately 165 units, with a total combined installed base of LENSAR Laser Systems and ALLY Systems increasing to about 410, reflecting a 23% increase year-over-year [3][4] - Selling, general, and administrative expenses rose to $11.7 million in Q2 2025, a 72% increase from $6.8 million in Q2 2024, largely due to acquisition-related costs associated with the merger with Alcon [5][6] - Research and development expenses increased slightly to $1.4 million in Q2 2025 from $1.3 million in Q2 2024 [6] Market Position - LENSAR's laser systems accounted for over 21% of total U.S. cataract procedures in Q2 2025, marking a 3% increase from the previous year [3] - The company continues to focus on advanced robotic laser solutions for cataract treatment, positioning itself as a leader in the medical technology sector [11]

Core Insights - LENSAR, Inc. reported a strong start to 2025 with a 34% increase in revenue and a 33% rise in worldwide procedure volumes compared to the first quarter of 2024 [2][3] - The company placed 14 ALLY Robotic Laser Cataract Systems in the first quarter of 2025, contributing to a total installed base of approximately 150 systems [3][4] - The company is in the process of a proposed merger with Alcon Research, LLC, which has led to increased acquisition-related costs [4][8] Financial Performance - Total revenue for Q1 2025 was $14.2 million, up from $10.6 million in Q1 2024, marking a $3.6 million increase [3][4] - Recurring revenue for the quarter was $11.5 million, representing an 81% recurring revenue percentage, although this is down from 90% in the previous year [4] - The net loss for Q1 2025 was $27.3 million, compared to a net loss of $2.2 million in Q1 2024, primarily due to changes in warrant liability [6][7] Operational Highlights - The company’s laser systems accounted for approximately 22% of total U.S. procedures in Q1 2025 [3] - Selling, general, and administrative expenses increased by 64% to $11.1 million, largely due to acquisition-related costs associated with the Alcon merger [4] - Research and development expenses rose slightly to $1.5 million, a 6% increase from the previous year [5] Cash Position - As of March 31, 2025, LENSAR had cash, cash equivalents, and investments totaling $25.2 million, an increase from $22.5 million at the end of 2024 [8]

31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company’s total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, ...